CHU Caremeau
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
At CHU Caremeau in Nimes, the infectious diseases team is involved in research on Staphylococcus aureus bacteremia, with a focus on improving outcomes for patients facing serious bloodstream infection. This work is aimed at evaluating treatment effectiveness and understanding which interventions may reduce mortality and improve recovery.
- Research on Staphylococcus aureus bacteremia
- Focus on serious bacterial infection outcomes
- Studies assessing treatment effectiveness and survival
The site’s clinical activity in this area reflects a practical effort to support better care for patients with difficult-to-treat infections.
Digestive System Diseases
Clinical research at CHU Caremeau also includes Crohn's Disease, a chronic inflammatory condition of the digestive system. These trials are exploring new therapeutic approaches and measuring how well treatment can promote deeper healing of the bowel wall and improve disease control.
- Research on Crohn's Disease
- Focus on digestive system inflammation
- Studies evaluating therapy effectiveness and healing response
This area of work supports advances in gastroenterology by helping clarify how newer treatments may benefit patients with ongoing intestinal inflammation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1i-GETAID1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Caremeau
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Mirikizumab in Achieving Transmural Healing in Patients with Crohn's Disease | i-GETAID | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amoxicillin | 1 | Unknown | 2023-10-26 | 2023-10-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.